Navigation Links
Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting
Date:5/17/2012

cide if you need heart monitoring (electrocardiogram or ECG), or blood tests during your treatment with HALAVEN to watch for this problem. 

Liver and Kidney Problems

In patients with mild or moderate liver problems, and/or moderate kidney problems, a lower starting dose of HALAVEN is recommended.

Most Common Side Effects

The most common side effects reported in greater than or equal  to 25% of patients receiving HALAVEN were low white blood cells (82%), low red blood cells (58%), weakness/tiredness (54%), hair loss (45%), numbness, tingling or burning in your hands and feet (35%), nausea (35%), and constipation (25%).  The most common serious side effects reported in patients receiving HALAVEN were neutropenia with or without a fever (4% and 2%, respectively).

For full prescribing information for HALAVEN, please visit: http://www.halaven.com/sites/default/files/HALAVEN_full_Prescribing_Information.pdf

DACOGEN® (decitabine) for InjectionDacogen is a nucleoside metabolic inhibitor indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate- 2, and high-risk International Prognostic Scoring System groups. (1)

Important Safety InformationTreatment with DACOGEN is associated with neutropenia and thrombocytopenia. Complete blood and platelet counts should be performed as needed to monitor response and toxicity but at a minimum prior to each dosing cycle. After administration of the recommended dosage for the first cycle, treatment f
'/>"/>

SOURCE Eisai Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study
2. Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses
3. Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application
4. Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
5. Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
6. Eisai Enters Licensing Agreement with Johns Hopkins Brain Science Institute
7. Eisai Inc. and the Alzheimers Association Honor Community Pharmacist for Outstanding Service to Individuals with Alzheimers Disease
8. Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
9. Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting
10. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
11. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... BRAINTREE, Mass. , May 23, 2013  Haemonetics Corporation ... Chris Lindop , CFO & EVP-Business Development, will present ... Care Conference in Boston, MA on ... (Logo: http://photos.prnewswire.com/prnh/20120206/NE47232LOGO ) The public may ... About Haemonetics Haemonetics (NYSE: ...
(Date:5/23/2013)... PAUL, Minn. , May 23, 2013  MGC ... Corporation), a global medical technology company, today scheduled a ... second quarter of fiscal year 2013, ended April 30, ... on Thursday, May 30, 2013. The Company will report ... 2013 after the markets close on Thursday, May 30, ...
(Date:5/23/2013)... , May 23, 2013  Hadasit Bio-Holdings Ltd. ... of biotech companies, based on intellectual property developed ... Israel ,s foremost medical research center, today ... Ltd., received significant funding from the Israeli Ministry ... Scientist (OCS) to support product development and advance ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
... April 19, 2011 Cumberland Pharmaceuticals Inc. ... focused on hospital acute care and gastroenterology markets, today ... acquire the rights to ifetroban, a new Phase II ... the brand name Hepatoren™ (ifetroban) Injection and is evaluating ...
... 18, 2011 Two lawsuits were filed today on ... have failed.  The cases were filed on behalf of ... DePuy Orthopaedics, Inc., DePuy Inc., DePuy International, Ltd., Johnson ... Johnson & Johnson International, Inc. John David Hart of ...
Cached Medicine Technology:Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 2Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 3Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 4Recalled DePuy Hip Implant Lawsuits Filed in Fort Worth, Texas 2
(Date:5/24/2013)... Teams of highly respected Alzheimer,s researchers failed to replicate ... of this brain disease when they were published last ... results, presented online Feb. 9, 2012, suggested that the ... buildup of beta amyloid plaques (Aβ) a pathological ... mice. According to the authors of the 2012 report, ...
(Date:5/24/2013)... Angeles, CA (PRWEB) May 24, 2013 ... to present the 3rd Annual EB-5 Investment Summit: Dealmakers ... The Dealmakers Conference will focus on exploring alternative finance ... the latest market, legal and economic information, and updates ... professionals within the EB-5 industry. , "Our goal ...
(Date:5/24/2013)... Mike Stoler believes that there is much to be ... York. That’s why he hosts “Building New York—New ... And that’s why he invited Robert Glazer, Chief Executive ... single specialty practice in the greater New York area, ... and sub-specialists service communities throughout New York and New ...
(Date:5/24/2013)... to the National Institutes of Health, Stevens Johnson Syndrome (SJS) ... the skin and mucous membranes. SJS occurs most commonly ... (i). In the early stages SJS presents flu-like symptoms, ... it affects the mucous membranes such as the eyes, mouth ... eye causes conjunctivitis (pink eye). Inflammation of the mouth ...
(Date:5/24/2013)... York, New York (PRWEB) May 24, 2013 ... 101 Mobility® is a leading nationwide sales, ... solutions for both consumer and commercial applications. The ... vertical platform lifts, vehicle lifts for mobility devices, ... among others. 101 Mobility operates over 30 locations, ...
Breaking Medicine News(10 mins):Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 2Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 3Health News:Brian Su Organizes 3rd Annual EB-5 Investment Conference in Long Beach, California 2Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 2Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 3Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 4Health News:Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines 2Health News:Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines 3Health News:Cortec Closes Equity Transaction with 101 Mobility 2
... demand for transparency through publicly available healthcare data is on ... data for research, and for clinical trials data used to ... impact on research and policy making. A new report by ... Health Information at the University of Ottawa and the Children,s ...
... , THURSDAY, Sept. 15 (HealthDay News) -- Not enough ... the U.S. Centers for Disease Control and Prevention reveals. ... experts advise that although young people need the calcium, vitamin ... and older should consume low-fat milk and milk products to ...
... HealthDay Reporter , WEDNESDAY, Sept. 14 (HealthDay News) -- ... Republican presidential debate over the human papillomavirus vaccine for ... During the debate, Rep. Michele Bachmann of Minnesota ... girls in his state get the HPV vaccine to ...
... from breast and cervical cancer are rising in most countries, ... at younger ages, according to a new global analysis by ... University of Washington., Breast cancer cases more than doubled around ... 1980 to 1.6 million cases in 2010, a pace that ...
... , WEDNESDAY, Sept. 14 (HealthDay News) -- Most campaigns ... younger generations, excluding a large number of sexually active ... want this information, a new study suggests. , , ... older women are aware of the risks for sexually ...
... A Michigan State University professor is using a ... and socioeconomic disparities seen among health and medical researchers. ... of Medicine at MSU,s College of Human Medicine, will ... a short-term research education program aimed at under-represented, minority ...
Cached Medicine News:Health News:New report on creating clinical public use microdata files 2Health News:Not Enough Kids Drink Low-Fat Milk, U.S. Study Finds 2Health News:Health Experts Say HPV Vaccine Is Safe 2Health News:Health Experts Say HPV Vaccine Is Safe 3Health News:More women dying from breast and cervical cancer at a younger age in developing countries 2Health News:More women dying from breast and cervical cancer at a younger age in developing countries 3Health News:Older Women Can Benefit From Sex Ed Campaigns 2Health News:$1.1 million grant targets disparities among medical researchers 2
1.0 mm Micro System. The Titanium Micro System is also useful in the practice of ENT, Neurosurgery and Handsurgery....
... Codman Sofwire Cable ... bony fixation including sublaminar ... maxillo facial surgery, sternotomy ... cables and a complete ...
Specially designed combination of demineralized bone fibers and demineralized bone cubes that are both osteoinductive and osteoconductive. Packs well into bone defects. Eliminates the need to mix can...
Demineralized bone matrix dispensed in a syringe. DBM will be free of foreign matter. Demineralized bone matrix particle size 125 to 850 . Glycerol 70-88% by weight. Calcium content less than 8%....
Medicine Products: